Key points from article :
Juvenescence joins investment in Chrysea Labs, a company developing nutritional interventions that maintain antiaging mechanisms.
Juvenescence, through its JuvLife Division, has joined the 200M Fund portfolio, invested 3.7 million euros.
Juvenescence and Chrysea will collaborate to develop and commercialise one of Chrysea’s products.
A naturally occurring small molecule having benefits in maintaining cardiovascular, cognitive and immune function in aging individuals.
“The molecules developed by Chrysea are metabolites that induce autophagy in our bodies, clear out cellular debris and stimulate cellular regeneration essential for healthy ageing,” said Colin Watts, CEO of JuvLife.
